Granocyte G-CSF data

In a randomized Phase I cross-over study in 32 healthy adults in Sweden, RPR compared its Granocyte G-CSF to Amgen Inc.'s Neupogen G-CSF for their ability to mobilize CD34+ stem cells. The results d...